ProfileGDS5678 / 1432010_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 23% 21% 21% 21% 21% 23% 21% 21% 21% 22% 21% 22% 21% 21% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5669123
GSM967853U87-EV human glioblastoma xenograft - Control 22.5019521
GSM967854U87-EV human glioblastoma xenograft - Control 32.5043321
GSM967855U87-EV human glioblastoma xenograft - Control 42.4425321
GSM967856U87-EV human glioblastoma xenograft - Control 52.4548421
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.5961523
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5282721
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.479721
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4716721
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4965522
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4880321
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.481522
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5015121
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.493321